Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

PURPOSE: Tusamitamab ravtansine is an antibody–drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers a cytotoxic maytansinoid payload. In a phase I dose-escalation study, the maximum tolerated dose (MTD) was 100 mg/m(2) every 2 weeks (Q2W). Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, Josep, Bedard, Philippe L., Bang, Yung-Jue, Vieito, Maria, Ryu, Min-Hee, Fagniez, Nathalie, Chadjaa, Mustapha, Soufflet, Christine, Masson, Nina, Gazzah, Anas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461573/
https://www.ncbi.nlm.nih.gov/pubmed/37645622
http://dx.doi.org/10.1158/2767-9764.CRC-23-0284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461573/
https://www.ncbi.nlm.nih.gov/pubmed/37645622
http://dx.doi.org/10.1158/2767-9764.CRC-23-0284

Ejemplares similares